Announced details
Reduces BSA usage by more than 90%. More sensitive than existing products.
artience's synthetic polymers have an established track record in the market.
The companies have been in a business partnership since 1 July 2025. The product was developed by combining 免疫生物研究所's antibody, reagent kit and in vitro diagnostic technologies with artience's polymer materials and chemical synthesis technologies.
Representative Director and President: Takashima Satoru (髙島悟), Chuo-ku, Tokyo. The company applies its material design technologies, including color materials and polymers, and dispersion technologies to the life sciences field, and develops functional polymers for in vitro diagnostic reagents and other products.
No impact on consolidated results for the fiscal year ending March 2027 is expected. 免疫生物研究所 will promptly disclose any matters that should be announced in the future.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | ELISA kit for measuring sCLEC-2, Sciforiem® PL 1000 series |
| Counterparty | artience Co., Ltd. |
| Counterparty overview | Representative Director and President: Takashima Satoru (髙島悟), Chuo-ku, Tokyo. The company applies its material design technologies, including color materials and polymers, and dispersion technologies to the life sciences field, and develops functional polymers for in vitro diagnostic reagents and other products. |
| Relationship with the Company | The companies have been in a business partnership since 1 July 2025. The product was developed by combining 免疫生物研究所's antibody, reagent kit and in vitro diagnostic technologies with artience's polymer materials and chemical synthesis technologies. |
| Contract Date | 1 July 2025 (start of business partnership; basic agreement signed) |
| Launch date | Mid-July 2026 (sales scheduled to begin) |
| Applicable area | In vitro diagnostic reagents, Research reagents, Measurement of sCLEC-2 in blood |
| Quantitative Effects | Reduces BSA usage by more than 90%. More sensitive than existing products. |
| Usage history | artience's synthetic polymers have an established track record in the market. |
| Impact on Business Performance | No impact on consolidated results for the fiscal year ending March 2027 is expected. 免疫生物研究所 will promptly disclose any matters that should be announced in the future. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Replacing the raw material with a chemically synthesized additive will ensure stable raw material quality and supply, contributing to improved accuracy and quality stability of the test kits.